相关实验视频

Updated: Jul 27, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

在先进的抗/耐火小细胞肺癌中使用FOLFIRI:一项回顾性研究

Cyril Roussel-Simonin¹, Paul Gougis^1,2, Donia Lassoued¹

¹Department of Medical Oncology, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Paris, France.

Acta oncologica (Stockholm, Sweden)

|June 5, 2023

概括

福利瑞化疗在患有白金耐药或耐药小细胞肺癌 (SCLC) 的患者中表现出活性,显示出可接受的安全性. 需要进一步的前性研究来确认其作为SCLC新治疗选择的潜力.

科学领域:

在瘤学瘤学.
医学研究医学研究

背景情况:

小细胞肺癌 (SCLC) 的预后不好,对于抗或耐火病例的治疗选择有限.
托波特坎是一种标准治疗方法,但具有很高的毒性,促使人们探索替代方案.
用于神经内分泌瘤的治疗方案FOLFIRI与SCLC有相似之处.

研究的目的:

评估FOLFIRI化疗方案的疗效和安全性.
在患有白金耐药或耐火性SCLC的患者中评估FOLFIRI.

主要方法:

用FOLFIRI (2013-2021) 治疗的SCLC患者的医疗记录的回顾性分析.
客观应答率 (ORR) 是主要终点,次要终点包括应答持续时间,疾病控制率,无进展生存 (PFS),总生存 (OS) 和安全.
使用RECIST v1.1或EORTC标准进行响应评估.

主要成果:

其中包括34名患者;28名患者的反应可评估.
观察到总体ORR为14.7% (5/34),可评估患者的疾病控制率为50% (14/28).
中位数PFS为2.8个月,中位数OS为5.3个月. 3级或4级不良事件发生在38.2%的患者中,主要是喘息,中性质减退,血栓减退和腹,没有与治疗相关的死亡.

结论:

福利利在抗/耐火性SCLC中表现出一些活性和可接受的安全性.
由于研究的回顾性质,建议谨慎解释结果.
福利瑞可能是一个潜在的新疗法选择,需要在前性研究中进一步调查.

关键词:

5 - - 甲是一种甲.在FOLFIRII中,你会发现氨酸是一种氨酸.追溯研究是一项回顾性研究.小细胞肺癌是一种小细胞肺癌.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

Published on: January 22, 2021

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...